Filing Flows › Zevra Therapeutics (ZVRA) › Operating margin
Zevra Therapeutics (ZVRA) operating margin by quarter
Zevra Therapeutics' operating margin was 30.7% in Q3 2026 (third quarter 2026), -11.6 pts from Q2 2026. Over the last 4 quarters it ranged from 27.3% (Q4 2025) to 144.0% (Q1 2026).
| Quarter | Operating margin | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | 30.7% | -11.6 pts | — |
| Q2 2026 | 42.3% | -101.7 pts | — |
| Q1 2026 | 144.0% | +116.7 pts | — |
| Q4 2025 | 27.3% | — | — |
Q3 2026 at a glance
Zevra Therapeutics, Q3 2026: revenue $37.8M (+45% year over year), operating margin 30.7%, net earnings $19.2M, operating cash flow $10.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Zevra Therapeutics' operating margin?
Zevra Therapeutics' operating margin was 30.7% in Q3 2026 (third quarter 2026), -11.6 pts from Q2 2026.
How has Zevra Therapeutics' operating margin changed?
Over the last 4 quarters it ranged from 27.3% (Q4 2025) to 144.0% (Q1 2026).